222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

Our Mission

The National Hemophilia Foundation (NHF) Nevada Chapter is dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research.

News & Events

PRESS RELEASE





FOR IMMEDIATE RELEASE

MEDIA CONTACT:

Sigilon Therapeutics today reported a new development in the company’s phase 1/2 clinical study of SIG-001 in individuals with severe or moderately severe hemophilia. This follows the events of this past summer when the U.S. Food and Drug Administration (FDA) placed a clinical hold on the trial due to an unwanted inhibitor response in one of the three patients participating in the study.

Historically, data on infants and toddlers (ITs) with von Willebrand disease (VWD), particularly relevant to bleeding patterns, has been lacking. To address this absence of data, a team of researchers from the U.S. Hemophilia Treatment Center Network (USHTCN) and the Centers for Disease Control and Prevention conducted retrospective analysis of HTC patients with VWD who are less than two years of age. The data were obtained through the USHTCN. The results were published in the journal Blood Advances.

Advertisements

222 S. Rainbow Blvd
Suite 203
Las Vegas, Nevada 89145

© Nevada Chapter of the National Hemophilia Foundation 2021

Crafted by Firespring